Efficacy and Safety of a Tofacitinib-based Immunosuppressive Regimen After Kidney Transplantation: Results From a Long-term Extension Trial

BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor. This open-label, long-term extension (LTE) study (NCT00658359) evaluated long-term tofacitinib treatment in stable kidney transplant recipients (n = 178) posttransplant. METHODS: Patients who completed 12 months of cyclosporine (CsA) or tofa...

Descripción completa

Detalles Bibliográficos
Autores principales: Busque, Stephan, Vincenti, Flavio G., Tedesco Silva, Helio, O’Connell, Philip J., Yoshida, Atsushi, Friedewald, John J., Steinberg, Steven M., Budde, Klemens, Broeders, Emine N., Kim, Yon Su, Hahn, Carolyn M., Li, Huihua, Chan, Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Kidney Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133407/
https://www.ncbi.nlm.nih.gov/pubmed/30234149
http://dx.doi.org/10.1097/TXD.0000000000000819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133407/
https://www.ncbi.nlm.nih.gov/pubmed/30234149
http://dx.doi.org/10.1097/TXD.0000000000000819

Ejemplares similares